Trials / Completed
CompletedNCT03220945
Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer
A Comprehensive Yoga Program (SKY) as an Adjunct Therapy for Prostate Cancer - A Randomized Pilot Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 45 (actual)
- Sponsor
- Emory University · Academic / Other
- Sex
- Male
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
This randomized pilot trial studies the effect of comprehensive yoga program (SKY) in reducing stress, pain, and fatigue, and improving psychological well-being in patients with prostate cancer. SKY is one of the most widely used breathing techniques derived from yoga. SKY Yoga may improve quality of life in patients with prostate cancer.
Detailed description
PRIMARY OBJECTIVES: I. Determine any change in pain, fatigue and psychological well-being as a result of SKY in prostate cancer (PCa) patients. II. Assess changes in some physiological parameters in response to SKY in the same subjects, compare these with those from Part 1, and assess whether these translate into clinical effects. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (Control Group): Patients undergo collection of blood, saliva, and hair samples after signing consent (pre-test 1), within 6-8 weeks after pre-test 1 (post-test 1), and within 2-4 months after post-test 1 (post-test 2). Patients may receive yoga instruction for 1 week after post-test 2. ARM II (Yoga Group): Patients receive yoga instruction over approximately 3 hours daily for 5 days of week 1 and over 2 hours once a week of weeks 2-13. Patients also undergo collection of blood, saliva, and hair samples within 2 months prior to starting yoga instruction, within weeks 2-3, and within weeks 14-15.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Yoga | Receive yoga instruction |
Timeline
- Start date
- 2016-01-06
- Primary completion
- 2023-04-27
- Completion
- 2023-04-27
- First posted
- 2017-07-18
- Last updated
- 2024-06-25
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03220945. Inclusion in this directory is not an endorsement.